Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aquestive Therapeutics, Inc.
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 3, 2026
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
October 27, 2026
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
October 15, 2026
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
September 17, 2026
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
September 1, 2026
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 19, 2026
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
August 18, 2026
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
1
2
Next Page
→